The global biosimulation market is set for significant growth, projected to reach approximately USD 20 billion by 2034, expanding at a CAGR of around 17%. This growth is driven by the increasing adoption of model-informed drug development (MIDD) strategies, which enhance drug behavior prediction and optimize dosing while minimizing costly clinical trials. North America currently leads the market, bolstered by a strong pharmaceutical sector and regulatory support for simulation-based evidence in drug development. Key players include Certara, Simulations Plus, and Schrödinger, among others. The integration of advanced technologies like AI and high-performance computing further fuels this market’s expansion.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/sectors/healthcare/articles/global-biosimulation-market-poised-phenomenal-170000900.html
